HeartFlow: 3 Key Takeaways for Long-Term Investors
HeartFlow raised its full-year 2026 revenue guidance to $262-264 million, with Q3 revenue growing 57% year-over-year. The company's Plaque Analysis software demonstrated a 34% reduction in major cardiovascular events in clinical trials, accelerating hospital adoption. Management initiated clinical trials targeting asymptomatic patients to expand the addressable market by $6 billion to $11 billion total, with expectations to achieve cash flow profitability by mid-2028.
